Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies

Purpose: The present study aimed to study the immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies. Materials and Methods: This prospective cohort study of hematology patients aimed to evaluate their antibody levels against the receptor-binding domain of the severe...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental vaccine research (Seoul) 2023, Vol.12 (2), p.107-115
Main Authors: Chayapa Thookhamme, Manassamon Navinpipat, Aimwipa Sasakul, Pakthipa Pattarakosol, Kamoltip Lertchaisataporn, Kriangkrai Tawinprai, Pannee Praditsuktavorn
Format: Article
Language:Korean
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: The present study aimed to study the immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies. Materials and Methods: This prospective cohort study of hematology patients aimed to evaluate their antibody levels against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 spike protein and seroconversion rates following two doses of the ChAdOx1 nCoV-19 vaccine. Between June and July 2021, we enrolled 61 patients and included 44 patients in our analysis. Antibody levels were assessed 8 and 4 weeks after the first and second injections, respectively, and compared with those of a healthy group. Results: Eight weeks after the first dose, the geometric mean antibody level was 1.02 binding antibody units (BAU)/mL in the patient group and 37.91 BAU/mL in the healthy volunteer group (p
ISSN:2287-3651
2287-366X